The United Kingdom and the United States have agreed to a important bilateral deal that will maintain no duties on UK medicine products going into the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This pledge guarantees that duties on these key products will be held at nothing for a timeframe of 36 months.
This development is in response to earlier threats to dramatically increase duties on patented pharmaceutical products, with potential rates discussed as high as 100%.
"This deal with the Britain reinforces the worldwide climate for innovative medicines and introduces much-needed balance to U.S.–U.K. medicine commerce," an announcement noted.
Economic Importance
Pharmaceuticals are one of the Britain's largest exports to the United States, which is by far the biggest buyer for leading British pharmaceutical firms.
Export figures indicate that in the year leading up to September, the UK exported drugs totaling £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This deal safeguards work, stimulates investment and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Detailed NHS Changes
The deal involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to stay within budget will be capped at 15%. Last year, repayments topped 20%.
Recent Tensions
The pact follows a protracted dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were intensified by claims that American consumers were paying significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been announced toward American operations.
The Science Minister stated that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
